$287 Million is the total value of Opaleye Management Inc.'s 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLRX | Exit | BIOLINERX LTDsponsored ads | $0 | – | -16,667 | -100.0% | -0.01% | – |
| MGTX | Exit | MEIRAGTX HLDGS PLC | $0 | – | -10,000 | -100.0% | -0.04% | – |
| OPTN | Exit | OPTINOSE INC | $0 | – | -90,970 | -100.0% | -0.14% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -575,000 | -100.0% | -0.15% | – |
| LUMO | Exit | LUMOS PHARMA INC | $0 | – | -46,576 | -100.0% | -0.17% | – |
| NPCE | Exit | NEUROPACE INC | $0 | – | -116,324 | -100.0% | -0.18% | – |
| Exit | JOURNEY MEDICINE CORP | $0 | – | -259,293 | -100.0% | -0.26% | – | |
| CMRX | Exit | CHIMERIX INC | $0 | – | -365,000 | -100.0% | -0.29% | – |
| IMPL | Exit | IMPEL PHARMACEUTICALS INC | $0 | – | -255,250 | -100.0% | -0.51% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -577,250 | -100.0% | -0.76% | – |
| MRUS | Exit | MERUS N.V. | $0 | – | -253,200 | -100.0% | -2.10% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -292,700 | -100.0% | -2.17% | – |
| CUTR | Exit | CUTERA INC | $0 | – | -147,700 | -100.0% | -2.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.